Cytokinetics®

ACACIA-HCM Topline Results

May 5, 2026

ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM

Full results to be presented at upcoming medical meeting

Primary Endpoints	Change from Baseline to Week 36 LSM (95% CI)		*Aficamten* vs Placebo LSM (95% CI)	p-value
	Aficamten	Placebo		
KCCQ-CSS	11.4 (9.6 – 13.2)	8.4 (6.6 – 10.2)	**3.0 (0.5 - 5.5)**	0.021
pVO_2 (ml/kg/min)	0.64 (0.32 – 0.95)	-0.03 (-0.35 – 0.28)	**0.67 (0.22 - 1.1)**	0.003

Statistically significant (p<0.001) improvements observed in key secondary endpoints:

1. Proportion of participants with improvements in NYHA Functional Class
2. Composite z-score of ventilatory efficiency and pVO_2
3. N-terminal pro-B-type natriuretic peptide (NT-proBNP)

No new safety signals identified

% participants completing planned dosing:
Similar between groups
(88.4% on *aficamten* vs. 90.3% on placebo)

LVEF <50%:
27 (10%) on *aficamten* vs. 2 (1%) on placebo;

2 participants on *aficamten* had a serious adverse event of HF associated with LVEF <50%

Treatment Interruptions
Treatment interruptions due to LVEF <40% occurred in 3% of patients on *aficamten*

nHCM: non-obstructive hypertrophic cardiomyopathy; pVO_2: peak oxygen uptake; LSM: least squares mean; CI: confidence interval; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; NYHA: New York Heart Association; CV: cardiovascular; HF: heart failure; LVEF: left ventricular ejection fraction; AE: adverse event

MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

ACACIA-HCM: Phase 3 Trial of *Aficamten* in nHCM

Robust & consistent improvements throughout treatment period

LS Mean Change from Baseline in KCCQ-CSS



** EoT visit includes participants who completed treatment at any time point beyond week 36*

Change from Baseline to Week 36 in pVO_2



nHCM: non-obstructive hypertrophic cardiomyopathy; LS: least squares; KCCQ-CSS: Kansas City Cardiomyopathy Questionnaire Clinical Summary Score; LSM: least squares mean; EOT: End of Treatment; EOS: End of Study; pVO_2: peak oxygen uptake

MYQORZO is only approved in the U.S., China and the EU for the treatment of adults with symptomatic oHCM.

Cytokinetics®